| Gene symbol | BCL2 | Synonyms | Bcl-2, PPP1R50 | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q21.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | BCL2 apoptosis regulator | ||||
| GTO ID | GTC1173 |
| Trial ID | NCT00005032 |
| Disease | Lung Cancer |
| Altered gene | Bcl-2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Genasense|G3139|oblimersen sodium |
| Co-treatment | paclitaxel |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | A Phase I/II Study of G3139, a BCL-2 Antisense Oligonucleotide, Combined With Paclitaxel for the Treatment of Recurrent Small Cell Lung Cancer |
| Year | 2000 |
| Country | United States |
| Company sponsor | University of Chicago |
| Other ID(s) | 10117|UCCRC-10017|NCI-T98-0091 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||